Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival

被引：0
作者：
Vicente Morales-Oyarvide
Douglas A Rubinson
Richard F Dunne
Margaret M Kozak
Justin L Bui
Chen Yuan
Zhi Rong Qian
Ana Babic
Annacarolina Da Silva
Jonathan A Nowak
Natalia Khalaf
Lauren K Brais
Marisa W Welch
Caitlin L Zellers
Kimmie Ng
Daniel T Chang
Rebecca A Miksad
Andrea J Bullock
Jennifer F Tseng
Richard S Swanson
Thomas E Clancy
David C Linehan
Jennifer J Findeis-Hosey
Leona A Doyle
Jason L Hornick
Shuji Ogino
Charles S Fuchs
Aram F Hezel
Albert C Koong
Brian M Wolpin
机构：
[1] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology
[2] Wilmot Cancer Institute,Department of Medicine, Division of Hematology and Oncology
[3] University of Rochester Medical Center,Department of Radiation Oncology
[4] Stanford Cancer Institute,Department of Epidemiology
[5] Harvard TH Chan School of Public Health,Department of Pathology
[6] Brigham and Women’s Hospital and Harvard Medical School,Division of Gastroenterology
[7] Hepatology,Department of Hematology and Oncology
[8] and Endoscopy,Department of Surgery
[9] Brigham and Women’s Hospital,Department of Surgery
[10] Beth Israel Deaconess Medical Center and Harvard Medical School,Department of Surgery
[11] Beth Israel Deaconess Medical Center and Harvard Medical School,Department of Pathology
[12] Brigham and Women’s Hospital and Harvard Medical School,Department of Radiation Oncology
[13] University of Rochester Medical Center,undefined
[14] University of Rochester Medical Center,undefined
[15] The University of Texas MD Anderson Cancer Center,undefined
来源：
British Journal of Cancer | 2017年 / 117卷
关键词：
pancreatic cancer; lymph node metastases; staging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1874 / 1882
页数：8
相关论文
共 294 条
[11]  
Weiss MJ(2010)Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 1073-1081
[12]  
Hruban RH(2004)A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 1200-1210
[13]  
Gonen M(2013)Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial JAMA 310 1473-1481
[14]  
Klimstra DS(2007)Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 267-277
[15]  
Mino-Kenudson M(2004)Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation Stat Med 23 2109-2123
[16]  
Basturk O(2011)Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the US Intergroup/RTOG 9704 phase III trial Ann Surg Oncol 18 1319-1326
[17]  
Saka B(2008)Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 1019-1026
[18]  
Balci S(2003)Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience World J Surg 27 324-329
[19]  
Postlewait LM(2016)Prognostic role of log odds of lymph nodes after resection of pancreatic head cancer J Gastrointest Surg 20 1707-1715
[20]  
Knight J(2006)Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database Ann Surg Oncol 13 1189-1200
12345678910